#Spain #Barcelona #ESTEVE #Caprelsa® #Medullary Cancer

ESTEVE's Acquisition of Caprelsa®: A Significant Step for Cancer Treatment

In a significant move towards bolstering its portfolio of specialized medications, ESTEVE has announced an agreement with Sanofi to acquire the rights to Caprelsa® (vandetanib) in more than 50 countries. This medication is instrumental in the treatment of medullary thyroid cancer, a rare yet aggressive form of thyroid cancer affecting both adults and children above the age of five.

Understanding Medullary Thyroid Cancer

Medullary thyroid cancer (MTC) arises from the parafollicular C cells, which are responsible for the secretion of calcitonin, a hormone involved in calcium homeostasis. This type of cancer can be particularly challenging to treat, often necessitating surgical intervention as the primary treatment. However, drugs like Caprelsa® that inhibit protein tyrosine kinase function play a crucial role in managing the disease by reducing blood supply to the cancer cells, thereby impeding their growth and proliferation.

José María Giménez-Arnau, ESTEVE's Chief Scientific Medical Officer, emphasized the company’s commitment to improving patient outcomes in the face of a healthcare landscape marked by significant unmet needs. "Medullary thyroid carcinoma is a rare neuroendocrine tumor capable of producing calcitonin from parafollicular cells. With the adoption of vandetanib, we can offer patients hope by slowing down or potentially reversing tumor growth. We are honored to support patients and healthcare professionals in this fight,” he stated.

ESTEVE's Strategic Growth Plan

This acquisition is not just about expanding product lines; it's a strategic move within ESTEVE's broader ambition to transition into a highly specialized pharmaceutical entity targeting rare and ultra-rare diseases. Earlier in 2024, the company took significant steps by acquiring a business focused on endocrinology and onco-endocrinology, adding three new drugs to its inventory aimed at treating conditions like endogenous Cushing's syndrome and adrenocortical carcinoma.

Just last month, ESTEVE also obtained a license for a biologic intended for the treatment of severe primary insulin-like growth factor 1 deficiency in young patients aged between two and eighteen. This expansion underscores the company's resolve to address high medical needs through internationally recognized specialized treatments.

Looking Ahead

Jacob Tolstrup, the Chief Commercial Officer at ESTEVE, expressed his pride regarding the expansion of their specialized therapy portfolio. "The introduction of Caprelsa® into our range will elevate our ability to enhance patient quality of life globally. It reflects our ongoing international expansion focused on severely unmet healthcare needs," he remarked.

As this acquisition moves forward, it remains subject to regulatory approvals, but the potential impact of Caprelsa® on patients suffering from medullary thyroid cancer is anticipated with considerable optimism. By investing in innovative therapies like vandetanib, ESTEVE is making strides toward fulfilling the vital demand for effective cancer treatments across the globe.

Conclusion

The integration of Caprelsa® into ESTEVE's offerings marks a turning point for the company and its stakeholders. It is not merely a business strategy; it is a commitment to providing essential resources and medications to those battling challenging health issues. As the pharmaceutical landscape evolves, ESTEVE's efforts to become a leading provider of specialized care are set to positively influence the lives of countless individuals, honing in on the specifics of patient needs while contributing to the worldwide fight against cancer.